Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients With Type 2 Diabetes
Detection methods in sports testing WADA-level testing uses significantly more sophisticated methodology than standard employment drug screening
doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review
View the full national GLP-1 Access Report Most recent BCBS formulary updates reviewed: January 6, 2026 BCBS Coverage Changes for 2026 Several BCBS affiliates have announced coverage changes for 2026
The liver prioritizes metabolizing alcohol over maintaining blood glucose, which means glucose can drop dangerously hours after drinking, including during sleep
Khunti K, Seidu S, Kunutsor S, Davies M (2017) Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis
